Press Releases

Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian Cancer
June 6, 2022
Verastem Oncology Awarded Pancreatic Cancer Action Network’s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer
May 18, 2022
Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
May 9, 2022
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 4, 2022
Verastem Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
March 28, 2022
Verastem Oncology Provides Financial Update to Support Development of VS-6766 and Defactinib in RAS Pathway-Driven Tumors
March 28, 2022
Verastem Oncology Names Preeminent Oncology Researcher Channing Der, PhD, to its Scientific Advisory Board
March 24, 2022
Verastem Oncology Outlines Key 2022 Strategic Priorities and Upcoming Catalysts for Advancing VS-6766 as a Backbone of Therapy for RAS Pathway-Driven Cancers
January 11, 2022
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 7, 2022
Verastem Oncology to Participate in Upcoming Investor Conferences
January 4, 2022

E-mail Alerts

You may automatically receive Verastem Oncology financial information by e-mail. To choose your options for e-mail notification, please enter your e-mail address below and click Submit.

Investor Contact

getty
Ajay Munshi

Investor Relations
781.469.1579
info@verastem.com

Nate LiaBraaten

Argot Partners
+1 212-600-1902
nate@argotpartners.com

Investor Kit
img